European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. The EMCDDA exists to provide the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.

Mission

The EMCDDA was set up to provide 'factual, objective, reliable and comparable information concerning drugs, drug addiction and their consequences'

Xchange Prevention Registry

Website
 - 
Xchange is an online registry dedicated to evidence-based prevention programmes, offering a wide array of thoroughly evaluated interventions. It serves as a valuable resource for implementers seeking effective strategies to address...

Launch event: European Drug Report 2023

Event Date
 - 
Brussels

How many new drugs were detected in Europe over the last year? What are the latest trends in drug production and trafficking? What substances are causing the most concern today? Find out more when the European Monitoring Centre for Drugs and Drug

Teens and substance use — what can parents do?

Video and audio recordings
Objective: To help adults manage risks relating to adolescent substance use in line with evidence-based prevention principles. Background: Smoking and drinking among 15–16-year-old school students are showing signs of decline, but there are...

EMCDDA Cocaine Hub

Website
Overview Cocaine is the hydrochloride salt produced from the leaves of the coca plant. Powder cocaine is typically snorted and less frequently injected. Crack is a smokable form of cocaine and is manufactured from cocaine hydrochloride...

Hexahydrocannabinol (HHC) and related substances

Book
Introduction The markets for hexahydrocannabinol (HHC) and related semi-synthetic cannabinoids (SSC) are rapidly evolving areas with relatively limited information currently available. The European situation presented in Section 1 can only...

Responding to stimulant use — developments in treatment

Video and audio recordings
Objective: To better understand current developments in the treatment of stimulant use. Background: Stimulant drugs are second only to cannabis as the most widely used class of illicit drug globally, accounting for 68 million past-year...

The future of drug monitoring in Europe until 2030

Book
 - 
Introduction Patterns of drug use and developments in the drug market in Europe are becoming more complex and dynamic, with major implications for drug monitoring and research. This observation prompted the European Monitoring Centre for...